Glancy Prongay & Murray LLP (GPM) announces an investigation on behalf of Zafgen, Inc. (Zafgen or the Company) (NASDAQ: ZFGN) investors concerning the Company and its officers possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected], or visit our website at www.glancylaw.com.
On March 11, 2019, Zafgen announced its decision to suspend plans to file an investigational new drug application for ZGN-1258, the Companys candidate for rare metabolic disorders based on a finding in rodent toxicology studies. According to the Company, data showed degeneration and other anomalies in rat muscle tissue to different degrees in both vehicle and dose arms of the studies.
On this news, shares of Zafgen fell $1.71, or 37% to close at $2.89 on March 12, thereby injuring investors.
If you purchased Zafgen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.